Senescence-Associated Beta-Galactosidase (SA-beta-gal)
Lysosomal beta-galactosidase activity detectable at suboptimal pH 6.0, reflecting massive lysosomal expansion in senescent cells.
Standard vs. Optimal Reference Ranges% Positive
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<5% positive cells in tissue biopsy
General reference distribution across unselected commercial populations.
<2% positive cells
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Accumulates due to increased lysosomal biogenesis in response to irreversible cell-cycle arrest and chronic proteostatic stress.
Differential Diagnosis
Elevated Levels (SA-beta-gal High)
- •Accumulation of senescent cells in aging tissues
- •Atherosclerotic plaque core senescence
- •Idiopathic pulmonary fibrosis
Low Levels (SA-beta-gal Low)
- •Youthful tissue architecture
- •Successful senolytic clearance (Dasatinib + Quercetin)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for SA-beta-gal
- Targeted organ system imaging or functional dynamic testing related to lysosomal biomarker of cellular senescence
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Senescence-Associated Beta-Galactosidase - The New England Journal of Medicine (2021). PMID: 34090124
- [2]SA-beta-gal Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Senescence-Associated Beta-Galactosidase (SA-beta-gal) into overall healthspan optimization.